Form 4: Oric Director Kunkel Granted 40,000 Stock Options

Oric Pharmaceuticals, Inc. Director Lori Anne Kunkel was granted 40,000 stock options with an exercise price of $8.17, vesting monthly over one year.

Summary

• Director Lori Anne Kunkel of Oric Pharmaceuticals, Inc. was granted 40,000 stock options.
• The options have an exercise price of $8.17 per share.
• The grant date for these options was January 2, 2026.
• The options will vest monthly, with 1/12th of the shares vesting on each one-month anniversary of January 2, 2026.
• The options expire on January 1, 2036.

Sentiment

Score: 6

Explanation: The grant of stock options to a director is a standard compensation practice that aligns the director's interests with long-term shareholder value, indicating continued commitment. This is a routine disclosure and not indicative of significant positive or negative operational news.

Positives

• The grant of stock options to a director aligns their interests with long-term shareholder value.
• The vesting schedule encourages continued service and commitment from the director.

Future Outlook

This filing is a disclosure of an insider transaction and does not contain forward-looking statements or guidance regarding the company's future performance or strategic direction, beyond the vesting and expiration dates of the options.

Industry Context

The granting of stock options to directors is a common and standard compensation practice across publicly traded companies, particularly within the biotechnology and pharmaceutical sectors, to align the interests of leadership with long-term shareholder value.

Comparison to Industry Standards

• Granting stock options to directors is a standard practice for public companies, especially in the biotech sector, to align director incentives with shareholder value. The specific number of options (40,000) and the exercise price ($8.17) would typically be benchmarked against peer companies of similar size, market capitalization, and stage of development, such as other clinical-stage oncology companies. However, this filing does not provide sufficient data for a detailed comparative analysis against specific comparable companies or projects.

Related Party Transactions

• The grant of 40,000 stock options to Director Lori Anne Kunkel constitutes a related party transaction, representing a form of director compensation.

Stakeholder Impact

• Shareholders: Potential positive impact through increased alignment of the director's interests with long-term shareholder value.
• Employees: No direct impact on employees is mentioned in this filing.

Next Steps

• The granted options will vest monthly over the next 12 months, starting February 2, 2026.
• The director may choose to exercise these options at any point after they vest and before their expiration date of January 1, 2036.

Key Dates

Recommendation

This Form 4 reports a routine equity grant to a director, which is a standard compensation practice aimed at aligning management and director interests with shareholders. It does not provide new fundamental information about the company's operations, financial performance, or strategic direction that would warrant a change in investment recommendation. Therefore, a 'hold' recommendation is appropriate as this filing alone does not alter the investment thesis.

Keywords

Oric Pharmaceuticals, ORIC, Stock Options, Insider Transaction, Form 4, Lori Anne Kunkel, Director Compensation, Equity Grant